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Abstract: Many randomized controlled trials (RCTs) have been
done on role of probiotics as a treatment modality in allergic rhinitis.
We conducted a review on the same. A systematic search of
published literature was done. RCTs comparing effect of probiotics
with placebo were included. A predefined set of outcome measures
were assessed. Continuous data were expressed as pooled standard-
ized mean difference (SMD) with 95% confidence interval (CI).
Dichotomous data were expressed as odds ratio with 95% CI. P
value0.05 was considered significant. RevMan version 5 was used
for all the analyses. Seven RCTs were eligible for inclusion. Probi-
otic intake improved quality of life score in patients with allergic
rhinitis [SMD 1.17 (95% CI 1.47, 0.86; P  0.00001)]. Other
parameter that improved with probiotic intake was decrease in the
number of episodes of rhinitis per year. There was no significant
change in blood or immunologic parameters in the probiotic group,
SMD 0.10 (95% CI 0.26, 0.06; P  0.22). Adverse events were
not significant. Probiotic therapy might be useful in rhinitis, but the
present data do not allow any treatment recommendations.
Key Words: respiratory allergy, lactobacillus, quality of life,
biofidobacterium, clinical trials
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INTRODUCTION
In the past 4 decades, there has been a marked increase in theprevalence of allergic rhinitis (AR) in urban settings and a
smaller rise in rural areas. In prosperous societies, 20–40%
of children suffer from AR.1 There is currently no cure for,
though a wide range of treatments are employed to control the
symptoms. Many of the treatment modalities do not act
through modification of inflammatory pathways which under-
lies the pathophygiologic basis of these diseases.
Probiotics are live micro-organisms that confer a ben-
eficial physiological effect on the host when administered in
adequate amounts.2 Limited evidence from systematic re-
views shows that probiotics are beneficial for treating infec-
tious diarrhea, preventing antibiotic-associated diarrhea, and
treating vaginal infections in pregnancy.3–5 They have been
formally investigated in a number of clinical trials for the
treatment of seasonal and perennial AR with variable results.
The aim of the present paper is to find whether probiotics are
effective in treatment of AR or not.
METHOD
Criteria for Considering Studies for This Review
Types of Studies
Randomized double-blind placebo-controlled trials
(RCTs).
Types of Participants
Participants in trials were of either sex and of any age.
Types of Interventions
Interventions consisted of daily treatment with probi-
otics or placebo (no probiotic bacteria), used for 2 weeks,
as an additive to standard antiallergic medications. All for-
mulations of probiotics (irrespective of the type, strain, and
concentration) were considered.
Types of Outcome Measures
A. Primary outcome
Quality of life score at the end of treatment
B. Secondary outcomes
Time (months) free from episodes.
Mean duration of an episode.
Number of episodes per year.
Changes in blood parameters/immunologic markers.
Time or duration was defined was defined as number of days to
resolution of specific outcome from initiation of treatment.
Change in symptom score was defined as the change in total
score over days per week. If the data were not available in the
required format, the authors were contacted for the information.
Search Methods for Identification of Studies
We systematically searched Medline, Cochrane Central
Register of Controlled Trials (CENTRAL), EMBASE and
previous reviews including cross references (all articles ref-
erenced), abstracts, and conference proceedings for all rele-
vant articles till June 2010. Following keywords: “probiotics”
OR “lactobacillus” OR “bifidobacterium” OR “bacterio-
therapy” OR “fermented milk” OR “lactic acid bacteria”
AND “supplement” OR “treatment” AND “allergy” OR “re-
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spiratory allergy” OR “allergic rhinitis” AND “children” OR
“pediatric” OR “adults” AND “clinical trial” OR “random-
ized controlled trial” were used for retrieval of relevant
articles. No language restrictions were applied. Two investi-
gators carried out the search independently. We then com-
bined all the searches and retrieved the relevant articles.
Manual search was made by going through the reference lists
of the retrieved articles and through Index Medicus and key
allergy, asthma, and immunology journals.
Data Collection and Analysis
Methodological Quality
Each included study was evaluated with the (previously
validated) 5-point Jadad scale to assess quality of trials by 2
independent reviewers.6 This scale assigns points as follows:
1. Was the study described as randomized? (0  no; 1 
yes)
2. Was the study described as double-blind? (0  no; 1 
yes)
3. Was there a description of withdrawals and drop-outs?
(0  no; 1  yes)
4. Was the method of randomization well described and
appropriate? (0  no; 1  yes)
5. Was the method of double blinding well described and
appropriate? (0  no; 1  yes)
6. Deduct 1 point if methods for randomization or blinding
were inappropriate.
Out of maximum possible score of 5, studies with scores 3
are supposed to be of good qualities were included in the
analysis.
Data Collection
Two review authors independently reviewed the results
for inclusion in the analysis. Design of the trial, comparator,
characteristics of study participants, number of participants,
type of intervention (dose, duration), and major outcomes
evaluated. Differences about study quality were resolved
through discussion. We recorded data on a prestructured data
extraction form. We assessed publication bias using the
Cochrane Collaboration’s ‘Risk of bias’ tool.
Study Descriptions
Information in relation to methodological quality, char-
acteristics of participants, interventions and outcome mea-
sures of each trial is provided in Table 1.
Data Synthesis
Continuous data were expressed as mean (SD) and
standardized mean difference (SMD) was obtained. The data
from various studies were pooled and expressed as pooled
SMD with 95% confidence interval (CI). Dichotomous data
were expressed as odds ratio (OR) with 95% CI. P value0.05
was considered significant. A fixed effects model was initially
conducted. If significant heterogeneity existed between trials,
potential sources of heterogeneity were considered and where
appropriate a random effects model was used. Inverted funnel
plot was generated for assessment of publication bias. RevMan
(Version 5) was used for all the analyses.
RESULTS
There were 53 hits obtained when the combined MeSH
terms were used (Fig. 1). From the initial search, 11 studies
were considered as potentially eligible. These studies were
further evaluated for eligibility. Seven studies were found to
be eligible for inclusion in this review (Table 1),7–13 and 4
studies were excluded.20–23 The quality of studies were good
with Jadad score varying from 3 to 5. Though most studies
had adequate randomization and blinded intervention, alloca-
tion concealment was not clear in all but one study.9 Not all
studies assessed all the out comes. For the studies in which
the results were expressed as mean (95% CI) or mean  SE,
the SD was derived from the available data. Seven included
studies enrolled a total of 616 participants (342 for treatment
and 274 as control subjects, which totaled 610 after losses to
follow-up) involving all age groups and both sexes. In 3 trials,
participants were administered probiotics on/before the onset of
pollen season and was continued until the completion of the
pollen season.10–12 Two studies provided data on the assessment
of quality of life7,8 and 3 about adverse-events.7,8,10
Primary Outcome Measure (Fig. 2)
Quality of Life Score at the End of Treatment
Two studies evaluated the quality of life score (fre-
quency, level of bother) in 170 patients.7,8 Compared with the
placebo group, intervention group showed an improvement in
the individual [change in frequency, SMD 0.90 (95% CI
1.34, 0.45; P  0.00001) and change in level of bother,
SMD 1.40 (95% CI 1.82, 0.98; P  0.00001)], and
overall quality of life score, SMD 1.17 (95% CI 1.47,
0.86; P  0.00001).
Secondary Outcome Measures
The results could not be pooled (except for blood/
immunologic parameters) as there were single study reports.
Time (Months) Free From the Episodes
Probiotic intake has no effect on the time free from
episodes of rhinitis. The mean (95% CI) time free from
episodes being 4.1 (3.1 to 5.0) months in the intervention
group versus 3.3 (2.4 to 4.3) months in the control group
(P value  0.9).
Mean Duration of an Episode
There was no significant difference between interven-
tion and control group, [mean 1.02 (95% CI 0.27 to 2.32)].
Number of Episodes Per Year
The episodes of rhinitis were significantly lower in the
intervention group with an adjusted odds ratio (95% CI) of
0.39 (0.19 to 0.82, P  0.01).
Changes in Blood or Immunologic Parameters
Data from 5 studies including 372 patients were used
for this analysis.9–13 Overall there was no significant change
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in blood or immunologic parameters in the probiotic group,
SMD 0.10 (95% CI 0.26, 0.06; P  0.22).
Side-Effects Noted (If Any)
None of the 7 studies reported a definition of what
constituted an adverse event. Two of the 3 studies, that did
monitor for adverse events reported absence of adverse
events.7,8 The third, reported 14 minor adverse events (in-
cluding cold, diarrhea, vomiting) but not the group (treatment
or control) in which they occurred.10
Publication Bias
To assess whether there was a bias in the published
literature, funnel plot was constructed using the SMD and
1/SE (standard error of mean) of SMD values obtained from
studies for one of the secondary outcome measures (serum
total IgE level) as there were paucity of data for primary
outcome measures. In the absence of a publication bias, such
a plot is expected to have a shape resembling an inverted
funnel.14 From the funnel plot generated, the possibility of
publication bias in the analysis could not be ruled out (Fig. 3).
DISCUSSION
In the present review, treatment with probiotic was
shown to improve the quality of life score of patients with AR
at the end of treatment. Other outcome showing improvement
with probiotic treatment was decrease in the number of
episodes of rhinitis per year. Pooling could not be undertaken
for many of the outcomes, as studies did not follow a
standard format for reporting of clinical trials. Many
reasons could account for the different outcomes among
studies wherever pooling was done in these trials and these
are: varied dose and intake period, the type and severity of
the symptoms involved were different, seasonal variation
of allergic symptoms and most importantly, the species
and strains of the probiotics differ.
FIGURE 1. Flow diagram of search results. RCTs  Ran-
domized controlled trials.
FIGURE 2. Primary outcome measures (change in quality of life score).
FIGURE 3. Funnel plot. Assessing publication bias using the
SMD and 1/SE of SMD values from serum total IgE level.
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As atopic disease have seasonal variation of symptoms,
the results could have been affected by time period of a
particular study. Three studies reported effects of probiotics
on allergic symptoms induced during pollen season of Japa-
nese cedar pollen (JCP) in patients with history of such
allergy (confirmed by symptoms and laboratory tests).10–12 In
these trials, participants were administered probiotics on/
before the onset of pollen season and were continued until the
completion of the pollen season. BB536-supplemented yo-
gurt has been demonstrated to have a pronounced promoting
effect on intestinal environments after 2 weeks of intake at a
dose of 100 g per day.15 For this reason, in these studies
probiotics was administrated before pollen exposure. Another
important reason is the difference regarding the validity of the
clinical effects of lactic acid bacteria among species and
strains. In fact, in vitro studies using human mononuclear
cells have indicated that there are strain-dependent differ-
ences in the ability of lactic acid bacteria to induce immuno-
regulatory monokines such as interleukin 12.16 Contribution
of the species- and strain-specific nature of lactic acid bacte-
ria on the efficacy of improving allergic symptoms should be
considered.
Placebo was poorly defined in most of the studies.
Many studies used nonfermented milk or plain yogurt as
placebo. A better control would have been fermented milk
without the addition of the probiotic bacteria or sterilized
fermented milk.17 The studies demonstrated the effect of
fermented milk containing a specific probiotic strain, but it is
not possible to conclude about the effect of probiotic
bacteria per se. Indeed, studies state that plain yoghurt has
some antiallergic effect and may have impact on rhinitis
and asthma.18,19 All these trials have used different doses
and durations and different strains of probiotics (eg, bi-
fidobacterium longum; lactobacillus strains). In all the
trials, the minimum dose of probiotics administered was
5 billion colony forming unit (CFU) and minimum
duration of administration was 1 month. It has been hy-
pothesized that some probiotic strains and/or their fermen-
tation products are responsible for improvement of allergic
rhinitis and the immunostimulatory effect of Lactobacillus
may be dose dependant.11,15,20,21
The effects of probiotics to modulate blood/immuno-
logic parameters associated with allergic symptoms should be
elucidated as some studies found beneficial effect on clinical
parameters without significant change in the immunologic
parameters. In this review, we found no significant overall
change in immunologic parameters in the probiotics group. In
all the trials, subjects were advised to continue antiallergic
medications during symptomatic period. In contrast to other
treatments such as histamine release inhibitors or antihista-
mines, the effects of probiotics are expected to be mild, with
a lag period in the expression of their effect. Uses of medi-
cations vary from patient to patient and some has carried over
effects (eg, steroids). Caution should be exercised during
interpretation of results because of probiotic bacteria effects
per se.
It is well known that systematic reviews are associated
with limitations, and the results obtained with these methods
should be analyzed accordingly. The numbers of patients
analyzed were small to reflect the data on the whole
population. Seven RCTs included a total of 616 subjects of
both age and sex with a paucity of clinically relevant
outcome measures. There was no uniformity in the defi-
nition of AR, and methodology of conducted trials. Indeed,
this meta-analysis highlights the paucity of good quality
clinical trials evaluating the role of probiotics in treatment
of subjects with AR. To conclude, though probiotic ther-
apy might be useful in rhinitis, the present data do not
allow any treatment recommendations.
ACKNOWLEDGMENTS
We wish to thank the South-Asian Cochrane network
for technical assistance.
REFERENCES
1. Allergic rhinitis and its impact on Asthma. ARIA workshop report.
J Allergy Clin Immunol. 2001;108 (Suppl):S147–S276.
2. Reid G, Sanders ME, Gaskins HR, Gibson GR, Mercenier A, et al. New
scientific paradigms for probiotics and prebiotics. J Clin Gastroenterol.
2003;37:105–118.
3. Allen SJ, Okoko B, Martinez E, et al. Probiotics for treating infectious
diarrhoea. Cochrane Database of Systematic Rev. 2007;1, No: CD003048.
4. D’souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in preventing
of antibiotic associated diarrhoea: Meta-analysis. BMJ. 2002;324:1361–
1364.
5. Othman M, Meilson JP, Alfirevic Z. Probiotics for preventing preterm
labour. Cochrane Database of Systematic Reviews. 2007;1, No: CD005941.
6. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports
of randomized clinical trials: is blinding necessary? Controlled Clin
Trials. 1996;17:1–12.
7. Peng G-C, Hsu C-H. The Efficacy and safety of heat-killed Lactobacillus
paracasei for treatment of perennial allergic rhinitis induced by house-
dust mite. Pediatr Allergy Immunol. 2005;16:433–438.
8. Wang MF, Lin HC, Wang YY, Hsu CH. Treatment of perennial allergic
rhinitis with lactic acid bacteria. Pediatr Allergy Immunol. 2004;15:152–
158.
9. Giovannini M, Agostoni C, Riva E, Salvini F, Ruscitto A, et al. A
randomized prospective double blind controlled trial on effects of
long-term consumption of fermented milk containing Lactobacillus
casei in pre-school children with allergic asthma and/or rhinitis. Pediatr
Res. 2007;62:215–220.
10. Tamura M, Shikina T, Morihana T, Hayama M, Kajimoto O, et al.
Effects of probiotics on allergic rhinitis induced by Japanese cedar
pollen: randomized double-blind, placebo-controlled clinical trial. Int
Arch Allergy Immunol. 2007;143:75–82.
11. Xiao JZ, Kondo S, Yanagisawa N, et al. Effect of probiotic Bifidobac-
terium longum BB536 in relieving clinical symptoms and modulating
plasma cytokine levels of Japanese cedar pollinosis during the pollen
season. A randomized double-blind, placebo controlled trial. J Investig
Allergol Clin Immunol. 2006a;16:86–93.
TABLE 2. Characteristics of Excluded Studies
Study Reason for Exclusion
Trapp 199320 Group 1 and 2 randomized and double-blinded, but
group 3 were those did not want to eat yogurt
Helin 200221 Patients had birch pollen allergy and mainly
rhino-conjunctivitis
Xiao 200722 Investigates symptoms induced by Japanese cedar
pollen in an environmental exposure unit
Ishida 200523 Randomized single-blind study with quality score  0
WAO Journal • September 2010 Probiotics in Respiratory Allergy
© 2010 World Allergy Organization 243
12. Xiao JZ, Kondo S, Yanagisawa N, et al. Probiotics in the treatment of
Japanese cedar pollinosis: a double-blind placebo-controlled trial. Clin
Exp Allergy. 2006b;36:1425–1435.
13. Ishida Y, Nakamura F, Kanzato H, Sawada D, Hirata H, et al. Clinical
effects of Lactobacillus acidophilus strain L-92 on perennial allergic rhinitis:
a double-blind, placebo-controlled study. J Dairy Sci. 2005;85:527–533.
14. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. BMJ. 1997;315:629–634.
15. Hatakka K, Savilahti E, Pon¨ka¨ A, et al. Effect of long term consumption
of probiotic milk on infections in children attending day care centres:
double blind, randomised trial. BMJ. 2001;322:1327–1329.
16. Miettinen M, Matikainen S, Vuopio-Varkila J, et al. Lactobacilli and
streptococci induce interleukin- 12 (IL-12), IL-18, and gamma interferon
production in human peripheral blood mononuclear cells. Infectious
Immunol. 1998;66:6058–6062.
17. Drug Information Association (DIA). The First International DIA Work-
shop: “Developing Probiotics as Foods and Drugs–Scientific and Reg-
ulatory Challenges.” Oct 16–17, 2006, Adelphi, MD. Available at:
http://www.isapp.net/IS_news.htm.
18. Marin ML, Tejada-Simon MV, Lee JH, Murtha J, Ustunol Z, Pestka JJ.
Stimulation of cytokine production in clonal macrophage and T-cell
models by Streptococcus thermophilus: comparison with Bifidobacte-
rium sp. and Lactobacillus bulgaricus. J Food Prot. 1998;61:859–864.
19. Aldinucci C, Bellussi L, Monciatti G, Passa`li GC, Salerni L, Passa`li D,
Bocci V. Effects of dietary yoghurt on immunological and clinical
parameters of rhinopathic patients. Eur J Clin Nutr. 2002;56:1155–1161.
20. Trapp CL, Chang CC, Halpern GM, et al. The influence of chronic
yogurt consumption on populations of young and elderly adults. Inter-
national Journal of Immunotherapy. 1993;IX:53–64.
21. Helin T, Haahtela S, Haahtela T. No effect of oral treatment with an
intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on
birch-pollen allergy: a placebo-controlled double-blind study. Allergy.
2002;57:243–246.
22. Xiao JZ, Kondo S, Yanagisawa N, et al. Clinical efficacy of probiotic
Bifidobacterium longum for the treatment of symptoms of Japanese
cedar pollen allergy in subjects evaluated in an environmental exposure
unit. Allergol Intl. 2007;56:67–75.
23. Ishida Y, Nakamura F, Kanzato H, Sawada D, Yamamoto N, et al. Effect
of milk fermented with Lactobacillus acidophilus Strain L-92 on Symp-
toms of Japanese Cedar Pollen Allergy: a randomized placebo-con-
trolled trial. Biosci Biotechnol Biochem. 2005;69:1652–1660.
Das et al WAO Journal • September 2010
© 2010 World Allergy Organization244
